Browsing Tag
Haemonetics Corporation
2 posts
CSL (ASX: CSL) names new CEO. Can 5% profit growth sustain its rally?
CSL shares have recovered sharply from their June lows as investors anticipate an earnings turnaround. The appointment of Deborah Waterhouse brings fresh leadership, but flat revenue guidance and persistent weakness at CSL Vifor leave an important question about how much recovery is already reflected in the share price.
October 25, 2026
Haemonetics (NYSE: HAE) acquires Vivasure Medical in €185m deal to expand vascular closure portfolio for structural heart procedures
Haemonetics acquires Vivasure Medical to expand its hospital closure portfolio with PerQseal Elite. Find out what this means for structural heart growth.
January 12, 2026